Drug
177Lu-J591
177Lu-J591 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
100%(2 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
completed250%
terminated125%
active_not_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
NCT00859781
completedphase_1
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
NCT00967577
terminatedphase_1
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
NCT03545165
completedphase_1
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
NCT00916123
Clinical Trials (4)
Showing 4 of 4 trials
NCT00859781Phase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
NCT00967577Phase 1
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
NCT03545165Phase 1
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
NCT00916123Phase 1
Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4